First Surrogate Endpoint in Osteoporosis Drug Trials with FNIH’s Dr. Tania Kamphaus episode artwork

EPISODE · Mar 18, 2026 · 39 MIN

First Surrogate Endpoint in Osteoporosis Drug Trials with FNIH’s Dr. Tania Kamphaus

from Xtalks Life Science Podcast · host Xtalks

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Tania Nayak Kamphaus, PhD, Associate VP of Science Partnerships at the Foundation for the National Institutes of Health (FNIH). In December 2025, the FDA qualified bone density DXA scans as the first surrogate endpoint for bone fractures in clinical trials of anti-osteoporosis drugs in post-menopausal women at risk for osteoporosis fracture. The surrogate endpoint will allow for measuring change in bone mineral density, rather than fracture occurrence, promising to speed the development of new drugs to treat osteoporosis. The decision was based on FNIH’s request for qualification through the work of the FNIH Biomarkers Consortium. Dr. Kamphaus leads patient engagement at FNIH and oversees programs across its Metabolic Disorders, Inflammation and Immunity and Women’s Health portfolios. She develops multi-stakeholder public-private partnerships involving NIH, FDA, non-profits and life sciences companies, and oversees target validation efforts within the Accelerating Medicines Partnership (AMP), as well as biomarker qualification initiatives in areas including preeclampsia and osteoporosis. Dr. Kamphaus conducted her postdoctoral fellowship at Columbia University and has a PhD in Molecular Genetics from The Ohio State University. Tune in to hear Dr. Kamphaus discuss the FDA’s decision on the new surrogate endpoint for bone fractures, the science behind the biomarker and the real-world impact it will have on the speed and cost of osteoporosis drug development.   For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Episode metadata supplied by the publisher feed · Published Mar 18, 2026

Embed this episode

NOW PLAYING

First Surrogate Endpoint in Osteoporosis Drug Trials with FNIH’s Dr. Tania Kamphaus

0:00 39:02

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Xtalks Life Science Podcast?

This episode is 39 minutes long.

When was this Xtalks Life Science Podcast episode published?

This episode was published on March 18, 2026.

Can I download this Xtalks Life Science Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!